LuminalB型乳腺癌TEC新辅助化疗疗效及影响因素分析(1)
摘要：目的 探讨Luminal B型乳腺癌TEC新辅助化疗的疗效及其影响因素。方法 对2016年1月～2018年6月于我院行4次TEC方案新辅助化疗的81例Luminal B型乳腺癌患者的临床病历资料进行回顾性分析，分析临床病理特征及相关指标的改变与疗效的相关性。结果 4周期新辅助化疗pCR率为4.94%，临床疗效与临床分期存在统计学意义(P<0.05)，是否获得pCR与年龄、BMI、绝经状态、原發肿瘤大小、肿瘤部位、确诊时淋巴结状态、PR、P53、Ki67均无统计学意义(P>0.05)。而除去4例获得pCR的患者，剩余77例乳腺癌患者新辅助化疗前后ER、PR的表达状态、Ki67指数的差异具有统计学意义(P<0.05)。结论 临床分期晚的患者新辅助化疗疗效相对较差，Ki67可能是乳腺癌新辅助化疗疗效的预测指标。
关键词：乳腺肿瘤;Luminal B;新辅助化疗;病理完全缓解;影响因素
中图分类号：R737.9 文献标识码：A DOI：10.3969/j.issn.1006-1959.2019.04.033
, http://www.100md.com
文章编号：1006-1959(2019)04-0104-03
Abstract：Objective To investigate the efficacy and influencing factors of neoadjuvant chemotherapy for Luminal B breast cancer. Methods The clinical medical records of 81 patients with Luminal B breast cancer who underwent 4 TEC regimen neoadjuvant chemotherapy in our hospital from January 2016 to June 2018 were retrospectively analyzed. The clinicopathological features and related indicators were analyzed. Correlation of efficacy. Results The pCR rate of neoadjuvant chemotherapy was 4.94%. The clinical efficacy and clinical stage were statistically significant (P<0.05). Whether pCR and age， BMI， menopausal status， primary tumor size， tumor location， and lymph node status at diagnosis were obtained. There were no significant differences in PR， P53 and Ki67 (P>0.05). Except for 4 patients with pCR， the expression of ER and PR and the Ki67 index of 77 patients with breast cancer before and after neoadjuvant chemotherapy were statistically significant (P<0.05). Conclusion Neoadjuvant chemotherapy is relatively ineffective in patients with late clinical stage. Ki67 may be a predictor of neoadjuvant chemotherapy for breast cancer.
, 百拇医药
Key words：Breast neoplasms; Luminal B;Neoadjuvant chemotherapy;Pathological complete remission; Influencing factors
乳腺癌(breast cancer)是一类高度异质性的恶性肿瘤，即使是同一种分子分型在临床表现及治疗反应上均存在较大的差异。新辅助化疗在乳腺癌的应用日益广泛，可降低肿瘤分期，为患者争取手术机会并提高保乳手术的概率。更重要的是，新辅助化疗后获得病理完全缓解的患者，其预后更好[1-3]。本研究旨在探讨Luminal B型乳腺癌患者接受新辅助化疗的疗效及其相关影响因素，为其治疗提供参考。
1资料与方法
1.1纳入与排除标准
1.1.1入选标准 ①单侧乳房发病;②经空心针穿刺初次确诊为浸润性乳腺癌(非特殊类型)并可获得完整免疫组化的患者;③肿瘤临床分期符合AJCC分期标准的T1～4N0～3M0，坚持按TEC方案新辅助化疗4周期，在第4次化疗后的2～3周内行手术治疗。
1.1.2排除标准 符合以下任意一项者：炎性乳腺癌、初次确诊或术前检查发现远处转移、新辅助化疗同时进行抗Her-2治疗、化疗前经麦默通活检或包块切除活检、不能按时接受化疗、合并其他系统恶性肿瘤和(或)既往有化疗史以及不能获得完整的临床资料的患者。, http://www.100md.com(黄雨 楼浩男 涂刚)
关键词：乳腺肿瘤;Luminal B;新辅助化疗;病理完全缓解;影响因素
中图分类号：R737.9 文献标识码：A DOI：10.3969/j.issn.1006-1959.2019.04.033
, http://www.100md.com
文章编号：1006-1959(2019)04-0104-03
Abstract：Objective To investigate the efficacy and influencing factors of neoadjuvant chemotherapy for Luminal B breast cancer. Methods The clinical medical records of 81 patients with Luminal B breast cancer who underwent 4 TEC regimen neoadjuvant chemotherapy in our hospital from January 2016 to June 2018 were retrospectively analyzed. The clinicopathological features and related indicators were analyzed. Correlation of efficacy. Results The pCR rate of neoadjuvant chemotherapy was 4.94%. The clinical efficacy and clinical stage were statistically significant (P<0.05). Whether pCR and age， BMI， menopausal status， primary tumor size， tumor location， and lymph node status at diagnosis were obtained. There were no significant differences in PR， P53 and Ki67 (P>0.05). Except for 4 patients with pCR， the expression of ER and PR and the Ki67 index of 77 patients with breast cancer before and after neoadjuvant chemotherapy were statistically significant (P<0.05). Conclusion Neoadjuvant chemotherapy is relatively ineffective in patients with late clinical stage. Ki67 may be a predictor of neoadjuvant chemotherapy for breast cancer.
, 百拇医药
Key words：Breast neoplasms; Luminal B;Neoadjuvant chemotherapy;Pathological complete remission; Influencing factors
乳腺癌(breast cancer)是一类高度异质性的恶性肿瘤，即使是同一种分子分型在临床表现及治疗反应上均存在较大的差异。新辅助化疗在乳腺癌的应用日益广泛，可降低肿瘤分期，为患者争取手术机会并提高保乳手术的概率。更重要的是，新辅助化疗后获得病理完全缓解的患者，其预后更好[1-3]。本研究旨在探讨Luminal B型乳腺癌患者接受新辅助化疗的疗效及其相关影响因素，为其治疗提供参考。
1资料与方法
1.1纳入与排除标准
1.1.1入选标准 ①单侧乳房发病;②经空心针穿刺初次确诊为浸润性乳腺癌(非特殊类型)并可获得完整免疫组化的患者;③肿瘤临床分期符合AJCC分期标准的T1～4N0～3M0，坚持按TEC方案新辅助化疗4周期，在第4次化疗后的2～3周内行手术治疗。
1.1.2排除标准 符合以下任意一项者：炎性乳腺癌、初次确诊或术前检查发现远处转移、新辅助化疗同时进行抗Her-2治疗、化疗前经麦默通活检或包块切除活检、不能按时接受化疗、合并其他系统恶性肿瘤和(或)既往有化疗史以及不能获得完整的临床资料的患者。, http://www.100md.com(黄雨 楼浩男 涂刚)